Oncolytic Virotherapy

‘In Situ Personalized Tumor Vaccine’

Armed with immune-modulatory payloads to tune tumor microenvironment

OV elicits anti-tumor immunity in the tumor microenvironment through its payloads.
OV alters the immunosuppressed tumor microenvironment through its payloads.
Intratumorally injected OV can trigger systemic anti-tumor response.

Virogin's innovative approaches to
overcome existing challenges of approved OVs

Limitation 1: Attenuated OVs (e.g., through gene deletion) weakens the virus's ability to replicate, resulting in limited clinical benefit.

Solution 1: Transcription & Translation Dual Regulation (TTDR) backbone to enhance viral replication in tumor cells.

üAt transcription level – Based on transcriptional control of the essential HSV-1 immediate-early protein using a tumor-associated promoter which, resulting in enhanced yet selective viral replication in tumors.

üAt translational level – Translational control of the neurovirulence factor ICP34.5 is achieved using multiple microRNA (miR)-binding sites.This miRNA regulation results in excellent safety .

Limitation 2: Currently used payloads have only a weak effect on inducing anti-tumor immune response.

Solution 2: Multiple cytokine payloads synergistically boost innate and adaptive immune responses to promote anti-tumor activity.

Our HSV-1 expressing IL-12, IL-15, IL-15Rα creates a strong immunostimulatory tumor microenvironment that can lead to the destruction of treated and untreated tumors (abscopal effect).

Multiple mechanisms of actions lead to multiple options of combos

OVs can be combined with several approved therapies to achieve better clinical benefits. There are myriad opportunities for OVs to help in inducing a robust immune response, leading to new synergistic mechanisms in the battle against cancer.